65,437 trials
Metastatic Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2 participants
Esophageal Carcinoma
Primary: Delayed Gastric Emptying Assessed Radiographically by Nuclear Medicine Emptying Study — 12; 14; 1; 3 Participants — p=0.773
Epilepsy
Primary: Percent Change From Baseline in 28-Day Convulsive Seizure Frequency During Ataluren Treatment Period — 723.17 percent change
Mantle Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants
Smoking Cessation · Weight Loss
Primary: Smoking Cessation — 25; 33 Participants
Insomnia · Psychosis
Primary: Insomnia Severity Index (ISI) — 11.6; 15.2 units on a scale — p=.04
Pneumonia, Bacterial
Primary: Number of Patients With Clinical Success as Judged by the Investigator — 158; 145; 6; 8 Participants — p==0.499
Severe Hypertriglyceridemia (sHTG)
Primary: Percent Change From Baseline in Fasting Triglycerides (TG) Level Following 12 Weeks of Repeated IV Doses of Evinacumab in Actual Cohort 3 Participants — 19.2; -37.2…
Frown Lines
Primary: Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation — 85.7; 86.7; 93.8; 100 percentage of subjects
Postoperative Delirium · Aortic Valve Stenosis
Primary: Number of Participants With Postoperative Delirium — 13; 41; 45 Participants — p=<0.0001
Postoperative Pain
Primary: Change in Buttock and Posterior Thigh Pain — -0.5; -0.2; -1.8; -1.5 score on a scale
Mild Cognitive Impairment · Healthy Aging
Primary: Comprehension/Recall of Results - Personal Information Score - PARTICIPANT — 82.40; 94.60; 69.40; 90.80 percentage correct
Motor Performance · Physical Activity
Primary: Motor Competence - Process Measures — 14.24; 14.35; 22.03; 17.26 score on a scale
HER2-positive Early Breast Cancer
Primary: Serum Trough Concentration (Ctrough) of Pertuzumab During Cycle 7 (Pre-Dose Cycle 8) — 69.9; 74.6 micrograms per millilitre (μg/mL)
Heart Failure
Primary: Attrition Rate — 1; 2 Participants